comprehensive -WSS

comprehensive

author：entertainment 2025-10-06 07:54:57 - browse：5

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： STAT letters to the editor on burnt

explore

focus

WSS

Pharma patents targeted by Biden in move to slash drug prices

The CDC's new social media misinformation war

Pfizer plans to depart BIO

Why Novartis is going to walk from its acquisition of MorphoSys

Why Novartis is going to walk from its acquisition of MorphoSys

Readout Newsletter: Amgen, Regeneron, BGI Group and more

entertainment

comprehensive

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Spinal cord stimulation reduces pain in amputees, study finds

As demand for Covid shots wanes, Moderna seeks its next success

Medicare Advantage plans can’t deny care with AI, CMS warns

DIEP, the 'gold standard' of breast reconstruction, is under threat

AstraZeneca stays mum on Medicare drug pricing negotiations

How to save PrEP access — and even expand it

Readout Newsletter: Amgen, Regeneron, BGI Group and more

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA needs staff influx to meet gene therapy needs, Marks says

focus

Adopting new red light myopia treatments may be short

AstraZeneca stays mum on Medicare drug pricing negotiations

A single Democrat is willing to weaken Medicare negotiation power

FDA needs staff influx to meet gene therapy needs, Marks says

Teach medical students about patients with intellectual disabilities

After sickle

explore

hotspot

focus

hotspot